Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 2/20 | 0.46 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.46 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.46 |
| ▸ | NPBWR1 | P48145 | 8/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186059 | 1.00 | PDE1A (0.46) | PDE1APDE1BPDE1CNPBWR1SMN1; SMN2 | |
| SCHEMBL2187234 | 0.88 | NPBWR1 (0.49) | PDE1APDE1BPDE1CNPBWR1SMN1; SMN2 | |
| SCHEMBL2544715 | 0.82 | NPBWR1 (0.55) | PDE1APDE1BPDE1CNPBWR1SMN1; SMN2 | |
| SCHEMBL2545681 | 0.73 | L3MBTL1 (0.57) | PDE1APDE1BPDE1CNPBWR1SMN1; SMN2 | |
| SCHEMBL16751117 | 0.70 | NPBWR1 (0.43) | PDE1APDE1BPDE1CNPBWR1SMN1; SMN2 | |
| SCHEMBL24763741 | 0.69 | NPBWR1 (0.54) | PDE1APDE1BPDE1CNPBWR1SMN1; SMN2 | |
| SCHEMBL24640498 | 0.67 | NPBWR1 (0.45) | PDE1APDE1BPDE1CNPBWR1SMN1; SMN2 | |
| SCHEMBL25756143 | 0.66 | NPBWR1 (0.63) | PDE1APDE1BPDE1CNPBWR1SMN1; SMN2 | |
| SCHEMBL14844531 | 0.66 | NPBWR1 (0.84) | NPBWR1SMN1; SMN2MCHR1ALDH1A1HTT | |
| SCHEMBL27077749 | 0.66 | NPBWR1 (0.55) | PDE1APDE1BPDE1CNPBWR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342179-B1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2015-05-27 | — | — | EP | disclosed |
| US-8536210-B2 | Compounds for inhibiting semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1) and uses thereof for treatment and prevention of diseases | SEMMELWEIS EGYETEM (HU) | 2013-09-17 | — | — | US | disclosed |
| US-8536210-B2 | Compounds for inhibiting semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1) and uses thereof for treatment and prevention of diseases | SEMMELWEIS EGYETEM (HU) | 2013-09-17 | — | — | US | disclosed |
| US-8536210-B2 | Compounds for inhibiting semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1) and uses thereof for treatment and prevention of diseases | SEMMELWEIS EGYETEM (HU) | 2013-09-17 | — | — | US | disclosed |
| US-20110263567-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2011-10-27 | — | — | US | disclosed |
| US-20110263567-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2011-10-27 | — | — | US | disclosed |
| US-20110263567-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2011-10-27 | — | — | US | disclosed |
| WO-2010029379-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263567-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | VCAM1, AOX1, AOC3 | PDE1A 2426/4885PDE1B 2023/4885PDE1C 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.